Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Irinotecan pharmacokinetics]

G G Chabot1, J Robert, F Lokiec

  • 1Hôpital Saint-Louis, Centre Hayem, Inserm U, Paris.

Bulletin Du Cancer
|February 5, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2.

British journal of cancer·2012
Same author

[Inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase: similarity and differences].

Revue de pneumologie clinique·2011
Same author

Radioimmunolymphoscintigraphy in the preoperative staging of primary breast cancer.

International journal of oncology·2011
Same author

Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients.

Cancer chemotherapy and pharmacology·2011
Same author

Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients.

British journal of cancer·2010
Same author

Optimization of cisplatin doses in a testicular cancer patient with acute renal failure.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2009
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
Same journal

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026
See all related articles

Irinotecan (CPT11) pharmacokinetics show dose-proportional increases in drug levels and significant correlations between drug exposure and toxicity, such as neutropenia and diarrhea. Understanding these relationships aids in optimizing CPT11 treatment for individual patients.

Area of Science:

  • Pharmacology and Toxicology
  • Drug Metabolism and Pharmacokinetics
  • Clinical Oncology

Background:

  • Irinotecan (CPT11) is a key chemotherapeutic agent, but its clinical use is limited by significant interpatient variability in pharmacokinetics and pharmacodynamics.
  • Understanding the disposition and metabolism of CPT11 and its active metabolite SN38 is crucial for optimizing therapeutic outcomes and managing toxicities.

Purpose of the Study:

  • To characterize the clinical pharmacokinetics of irinotecan (CPT11) and its active metabolite SN38.
  • To investigate the relationship between irinotecan pharmacokinetics and clinical outcomes, including toxicity and tumor response.

Main Methods:

  • Pharmacokinetic analysis using a 2 or 3 compartment model.
  • Quantification of irinotecan and SN38 plasma concentrations over time.

Related Experiment Videos

  • Assessment of drug-protein binding and metabolic pathways (carboxyesterase, UGT1A1, CYP3A4).
  • Correlation analysis between pharmacokinetic parameters (AUC) and clinical endpoints (toxicity, response).

    • Main Results:

    • Irinotecan exhibits a terminal half-life of 12 hours, volume of distribution of 168 L/m², and total body clearance of 15 L/m²/h.
    • Plasma concentrations (AUC) of irinotecan and SN38 increase proportionally with dose, despite significant interpatient variability.
    • SN38, 100-1000 fold more cytotoxic than irinotecan, circulates at lower concentrations but is highly protein-bound.
    • Significant correlations were observed between irinotecan/SN38 AUCs and leuko-neutropenia and diarrhea.
    • Tumor responses in Phase I trials suggest a dose-response relationship.

    Conclusions:

    • Irinotecan pharmacokinetics are characterized by dose proportionality and significant interpatient variability.
    • Pharmacokinetic-pharmacodynamic relationships link drug exposure to toxicity (neutropenia, diarrhea) and potentially tumor response.
    • These findings support individualized dosing strategies for irinotecan to improve clinical management, optimize toxicity control, and predict patient response.